PMC:3724972 / 21401-22155 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3724972","sourcedb":"PMC","sourceid":"3724972","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3724972","text":"Combined use of a somatostatin analog and a dopamine agonist for treatment of CD has been proposed on the basis of similar studies suggesting additive effects on growth hormone secretion from somatotroph adenomas [60]. In a study of 17 patients with CD, pasireotide monotherapy (100–250 mcg three times a day) normalized UFC levels in 5 patients, and addition of cabergoline (0.5–1.5 mg every other day) normalized UFC levels in 4 more patients. Among the remaining 8 patients, subsequent addition of ketoconazole (200 mg three times a day) normalized UFC levels in 6, leaving only 2 patients who still had elevated UFC levels. Thus, sequential therapy using these three agents shows promise but requires further studies of both efficacy and safety [61].","tracks":[{"project":"2_test","denotations":[{"id":"23673515-17413190-63233656","span":{"begin":214,"end":216},"obj":"17413190"},{"id":"23673515-20463350-63233657","span":{"begin":750,"end":752},"obj":"20463350"}],"attributes":[{"subj":"23673515-17413190-63233656","pred":"source","obj":"2_test"},{"subj":"23673515-20463350-63233657","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93b2ec","default":true}]}]}}